Financial Contrast: Mersana Therapeutics (MRSN) and Its Peers

Mersana Therapeutics (NASDAQ: MRSN) is one of 287 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Mersana Therapeutics to related businesses based on the strength of its analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Mersana Therapeutics and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mersana Therapeutics 0 0 4 0 3.00
Mersana Therapeutics Competitors 925 3348 11856 237 2.70

Mersana Therapeutics currently has a consensus price target of $23.67, suggesting a potential upside of 39.79%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 41.19%. Given Mersana Therapeutics’ peers higher probable upside, analysts plainly believe Mersana Therapeutics has less favorable growth aspects than its peers.

Earnings & Valuation

This table compares Mersana Therapeutics and its peers revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Mersana Therapeutics N/A N/A N/A
Mersana Therapeutics Competitors $290.27 million $35.99 million 58.47

Mersana Therapeutics’ peers have higher revenue and earnings than Mersana Therapeutics.

Insider & Institutional Ownership

76.7% of Mersana Therapeutics shares are owned by institutional investors. Comparatively, 49.7% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 17.5% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Mersana Therapeutics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Mersana Therapeutics N/A N/A N/A
Mersana Therapeutics Competitors -5,441.68% -162.70% -35.92%

Summary

Mersana Therapeutics beats its peers on 6 of the 10 factors compared.

About Mersana Therapeutics

Mersana Therapeutics, Inc. is a United States-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design ADCs with specific properties and manage the drug’s chances of attacking cancers. Its product candidates include XMT-1522 and XMT-1536. The ADC therapies treat cancer patients by engineering a drug conjugate with various anti-cancer agents and controlling when, where and how those agents are released. Dolaflexin is its Fleximer antibody drug conjugation platform, which pairs the Fleximer polymer with its linker chemistries to create ADC therapies. XMT-1522 is based on its Dolaflexin platform and has over 15 auristatin molecules per antibody. XMT-1522 is in Phase I clinical trial for various indications of cancers. XMT-1536 is in pre-clinical development.

Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2018 Ticker Report. Google+.